SEC Form 424B3 filed by Lakewood-Amedex Biotherapeutics Inc.

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-295497

PROSPECTUS SUPPLEMENT No. 2

(to Prospectus dated April 17, 2026)

LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC.

This prospectus supplement updates and supplements the prospectus dated April 17, 2026 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-295497). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 17, 2026 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Investing in our securities involves risks that are described in the “Risk Factors” section beginning on page 12 of the Prospectus.

Neither the U.S. Securities and Exchange Commission, nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement June 22, 2026.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 15, 2026

Lakewood-Amedex Biotherapeutics Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (941) 225-2515

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Securities registered pursuant to Rule 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.03. Material Modification to Rights of Security Holders.

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this report is incorporated herein by reference.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc (the “Company”) filed a Certificate of Change (the “Certificate of Change”) with the Secretary of State of the State of Nevada to effectuate a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding and authorized shares of common stock, par value $0.0001 per share (“Common Stock”). The Reverse Stock Split will become effective at 4:01 p.m., Eastern Time, on June 19, 2026, and the Company’s Common Stock will begin trading on a split-adjusted basis when the Nasdaq Stock Market (“Nasdaq”) opens on June 22, 2026. The Reverse Stock Split was unanimously approved by the Company’s Board of Directors on June 1, 2026.

As a result of the Reverse Stock Split, every ten (10) shares of the Company’s issued and outstanding Common Stock will be exchanged for one (1) share of Company’s Common Stock with any fractional shares being rounded up to the next higher whole share. Once effective, the Reverse Stock Split will reduce the current number of issued and outstanding shares of Common Stock from approximately 17,506,577 million to approximately 1,750,789 million. Equitable adjustments will be made to the number of shares of the Company’s Common Stock issuable upon exercise or conversion of the Company’s equity awards, preferred stock and warrants and the number of shares issuable under the Company’s equity incentive plans, as well as the applicable conversion prices and exercise prices for such equity awards, preferred stock and warrants, in accordance with their terms. In addition, concurrent with the Reverse Stock Split, a proportionate reduction will be made to the Company’s authorized shares of Common Stock such that the Company shall have 12,500,000 shares of authorized Common Stock after the effective time of the Reverse Stock Split.

The Company’s Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “LABT”, but the security has been assigned a new CUSIP number (51255A201).

The foregoing description of the Certificate of Change does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Change which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.